Focus of the Week
May 30, 2014
Specialty pharmaceuticals are currently the object of payer focus as one of the major drivers of increased pharmacy spending in 2014 and beyond.
March 31, 2014
Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.
March 31, 2014
As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.
July 03, 2013
Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.
April 22, 2013
Patients with relapsing-remitting multiple sclerosis experience an accumulation of central nervous system damage and associated cognitive and physical disability progression. With the widespread use of disease modifying therapies, health plans have experienced improved clinical outcomes for MS together with increasing associated pharmacy-related expenses.
March 20, 2013
On February 8, 2013, the US Food and Drug Administration approved pomalidomide (Pomalyst) for the treatment of patients with multiple myeloma who have received at least 2 previous myeloma therapies, including lenalidomide and bortezomib, but whose disease progressed while receiving these therapies or within 60 days of stopping the last therapy.
February 18, 2013
We only have to take a brief look back to see that 10 years ago, most specialty drugs were injectable agents used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and growth disorders. Today, the list of agents that is considered specialty includes many oral drugs and even some inhaled agents. In just more than 2 decades, the specialty drug market place has grown substantially.
January 17, 2013
The US Food and Drug Administration approval of tofacitinib (Xeljanz) in November 2012 represents a potential for significant change in the approach to the treatment of rheumatoid arthritis.